Literature DB >> 14764685

Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro.

Kenji Matsumoto1, Maki Terakawa, Kenju Miura, Shuhei Fukuda, Toshiharu Nakajima, Hirohisa Saito.   

Abstract

Apoptosis is an important cellular mechanism for controlling cell viability and proliferation. With respect to eosinophils, cytokines prolong their survival, whereas corticosteroids reduce their survival in vitro. CD30, a member of the TNFR family, is expressed on the surface of many cell types, including Hodgkin's lymphoma cells. CD30 is capable of inducing apoptosis after Ab treatment in some cell lines. To determine whether this surface structure is involved in apoptosis of human eosinophils, we examined its expression and the effect of anti-CD30 Ab treatment on the viability of eosinophils. Purified human eosinophils expressed low, but consistently detectable, levels of CD30. Immobilized, but not soluble, forms of anti-CD30 Abs (HRS-4 and Ber-H8) or recombinant mouse CD30 ligand exhibited an extremely rapid and intense survival-reducing effect on the eosinophils in the presence of exogenous IL-5; this effect was both concentration and time dependent. Furthermore, high concentrations of IL-5 could not reverse the reduced survival rates. After treatment with anti-CD30 Ab, gel electrophoresis of DNA extracted from the eosinophils demonstrated changes consistent with apoptosis. The immobilized F(ab')(2) of the anti-CD30 Ab failed to induce eosinophil apoptosis. The addition of anti-CD18 Ab also completely abrogated the induction of eosinophil apoptosis. Further examination using specific signal transduction inhibitors suggested the involvement of p38, mitogen-activated protein kinase kinase 1/2, and specific tyrosine kinase, but not NF-kappaB, in the induction of CD30-mediated eosinophil apoptosis. These data demonstrate that CD30 can modify eosinophil survival by causing an extremely rapid and intense induction of apoptosis through a tightly regulated intracellular signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764685     DOI: 10.4049/jimmunol.172.4.2186

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Origin, regulation and physiological function of intestinal oeosinophils.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Best Pract Res Clin Gastroenterol       Date:  2008       Impact factor: 3.043

Review 2.  Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders.

Authors:  Steven J Ackerman; Bruce S Bochner
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

Review 3.  Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.

Authors:  Lauren Shea; Neha Mehta-Shah
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

4.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

Review 5.  Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity.

Authors:  Takanori So; Seung-Woo Lee; Michael Croft
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

Review 6.  The NR4A nuclear receptor family in eosinophils.

Authors:  Ryoichi Hashida; Naganari Ohkura; Hirohisa Saito; Gozoh Tsujimoto
Journal:  J Hum Genet       Date:  2006-11-10       Impact factor: 3.172

7.  Eosinophil survival and apoptosis in health and disease.

Authors:  Yong Mean Park; Bruce S Bochner
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

Review 8.  Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Authors:  Aiko Nagayama; Leif W Ellisen; Bruce Chabner; Aditya Bardia
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

Review 9.  CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.

Authors:  Geetika Bhatt; Kami Maddocks; Beth Christian
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 10.  The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis.

Authors:  Ricardo F Antunes; Juan Carlos Kaski; Ingrid E Dumitriu
Journal:  J Biomed Biotechnol       Date:  2011-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.